Michael Ip, MD
Ophthalmology · Pasadena, CANPI 1982670402
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $164,083 of the $181,080 with a category attached, or 90.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 13.0%. Reporting peaked in 2019 at $48,791 and has fallen 62.8% since, to $18,140 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $1006.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$24K
- AbbVie$19K
- Apellis Pharmaceuticals, Inc.$16K
- Hoffmann-la Roche Limited$16K
- Boehringer Ingelheim$10K
- Novartis Pharma AG$10K
- plus $86K from 22 others
Across 102 payments — averaging $98,149 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$9M
- Regeneron$326K
- Genentech, Inc.$252K
- Apellis Pharmaceuticals, Inc.$202K
- Ocular Therapeutix, Inc.$76K
- AstraZeneca$38K
- plus $73K from 4 others
What the payments were for
- Consulting fees$164,08391%
- Speaking & faculty fees$5,1933%
- Travel & lodging$4,3592%
- Food & beverage$7,4454%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 38 | $23,618 |
| AbbVie(2 entities) | 24 | $19,359 |
| Apellis Pharmaceuticals, Inc. | 10 | $16,319 |
| Hoffmann-la Roche Limited | 4 | $15,700 |
| Boehringer Ingelheim | 4 | $10,089 |
| Novartis Pharma AG | 2 | $9,675 |
| Amgen | 9 | $9,286 |
| Novartis | 9 | $9,080 |
| Genentech, Inc. | 9 | $9,053 |
| Thrombogenics, Inc. | 3 | $9,000 |
| Carl Zeiss Meditec, Inc. | 3 | $8,550 |
| Eyepoint US, Inc. | 9 | $6,814 |
| Carl Zeiss Meditec USA, Inc. | 9 | $6,195 |
| Alimera Sciences, Inc. | 2 | $4,219 |
| Regeneron Healthcare Solutions, Inc. | 5 | $4,088 |
| Boehringer Ingelheim International GmbH | 3 | $3,800 |
| F. Hoffmann-la Roche AG | 1 | $3,693 |
| Aerie Pharmaceuticals, Inc. | 2 | $2,827 |
| Genentech USA, Inc. | 2 | $2,770 |
| Alcon | 2 | $2,446 |
| Biotissue Holdings Inc. | 1 | $1,500 |
| Bausch & Lomb Americas Inc. | 13 | $1,327 |
| Biocryst Pharmaceuticals, Inc. | 4 | $965 |
| Ocular Therapeutix, Inc. | 4 | $395 |
| Astellas Pharma US Inc | 4 | $143 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $79 |
| Coherus Oncology, Inc. | 1 | $68 |
| Leica Microsystems Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$14,655
- BEOVU$13,285
- EYLEA HD$12,450
- CIRRUS HD-OCT$10,104
- Jetrea$9,000
- VABYSMO$7,650
- Syfovre$5,430
- CLARUS$5,250
- BUPARLISIB$5,247
- YUTIQ$4,820
- ARTEVO 800$4,500
- Iluvien$4,200
- Non-Covered Product$4,106
- Lucentis$2,358
- VisuMax$2,304
- EYP-1901$1,850
- Prokera$1,500
- AmnioGraft$1,500
- QUATERA 700$1,500
- CALLISTO eye$1,500
How this compares
$181,080 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 11 | $909 |
| Prednisolone Acetate | 21 | $834 |
| Atropine Sulfate | 11 | $535 |
| Ketorolac Tromethamine | 24 | $323 |
| Latanoprost | 13 | $212 |
| Timolol Maleate | 18 | $42 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Pasadena
- Srinivas SaddaPasadena$1M
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.